United States Biotechnology & Medical Research

Avalo Therapeutics, Inc. (AVTX)

Track

Track

Avalo Therapeutics executives have engaged in significant selling activity over the past quarter, totaling approximately $750,000 in net value. These transactions, primarily planned sales by the CFO, follow a recent earnings report that missed expectations. The stock has experienced a 24.9% decline during this period, reflecting broader downward pressure on the company's market valuation.
Ticker: AVTX Exchange: NAS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Avalo Therapeutics, Inc.. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Sullivan Christopher Ryan Chief Financial Officer Officer
Transaction date
Planned sale
Price
471.31
Quantity 96,897 +28.5%
Value US$1,162,085
Sullivan Christopher Ryan Chief Financial Officer Officer
Transaction date
Planned sale
Price
188.36
Quantity 71,656 +5.2%
Value US$3,455,060
2.3
Doyle Mittie Chief Medical Officer Officer
Transaction date
Planned sale
Price
225.03
Quantity 89,710 -13.9%
Value US$4,453,365
Sullivan Christopher Ryan Chief Financial Officer Officer
Transaction date
Sale
Price
20.05
Quantity 31,031 -43.7%
Value US$622,324
CHRISTOPHER RYAN SULLIVAN Officer Officer
Transaction date
Proposed sale
Price
20.05
Quantity 31,031
Value US$622,221
Sullivan Christopher Ryan Chief Financial Officer Officer
Transaction date
Sale
Price
19.94
Quantity 3,749 -8.6%
Value US$74,762
Sullivan Christopher Ryan Chief Financial Officer Officer
Transaction date
Planned sale
Price
19.85
Quantity 37,945 -46.5%
Value US$753,333
2.3
Doyle Mittie Chief Medical Officer Officer
Transaction date
Planned sale
Price
20.00
Quantity 1,000 -1.9%
Value US$20,000
2.3
MITTIE DOYLE Officer Officer
Transaction date
Proposed sale
Price
19.59
Quantity 5,037
Value US$98,675
CHRISTOPHER RYAN SULLIVAN Officer Officer
Transaction date
Proposed sale
Price
19.94
Quantity 3,749
Value US$74,762
Riley Jennifer Chief Strategy Officer Officer
Transaction date
Sale
Price
19.59
Quantity 2,655 -6.7%
Value US$52,012
JENNIFER RILEY Officer Officer
Transaction date
Proposed sale
Price
19.59
Quantity 2,655
Value US$52,012
2.3
Doyle Mittie Chief Medical Officer Officer
Transaction date
Planned sale
Price
20.00
Quantity 679 -1.3%
Value US$13,580
2.3
MITTIE DOYLE Officer Officer
Transaction date
Proposed sale
Price
18.32
Quantity 679
Value US$12,439
2.3
Doyle Mittie Chief Medical Officer Officer
Transaction date
Planned sale
Price
20.00
Quantity 1,000 -1.9%
Value US$20,000
2.3
Doyle Mittie Chief Medical Officer Officer
Transaction date
Planned sale
Price
20.00
Quantity 4,654 -8.2%
Value US$93,080
2.3
Doyle Mittie Chief Medical Officer Officer
Transaction date
Planned sale
Price
18.00
Quantity 1,450 -2.7%
Value US$26,100
0.8
JONATHAN GOLDMAN Director Non-Executive Director
Transaction date
Proposed sale
Price
14.39
Quantity 42,833
Value US$616,226
2.3
Doyle Mittie Chief Medical Officer Officer
Transaction date
Planned sale
Price
16.00
Quantity 679 -1.4%
Value US$10,864
2.3
Doyle Mittie Chief Medical Officer Officer
Transaction date
Planned sale
Price
18.76
Quantity 3,000 -45.3%
Value US$56,280
Sullivan Christopher Ryan Chief Financial Officer Officer
Transaction date
Planned sale
Price
24.12
Quantity 18,606 -97.8%
Value US$448,818
CHRISTOPHER SULLIVAN Officer Officer
Transaction date
Proposed sale
Price
21.81
Quantity 18,606
Value US$405,797
VARKI PAUL Chief Legal Officer Officer
Transaction date
Planned sale
Price
23.71
Quantity 400 -9.9%
Value US$9,484
VARKI PAUL Chief Legal Officer Officer
Transaction date
Planned sale
Price
22.70
Quantity 9,253 -69.6%
Value US$210,029
VARKI PAUL Chief Legal Officer Officer
Transaction date
Planned sale
Price
21.22
Quantity 22,839 -63.2%
Value US$484,541
VARKI PAUL Chief Legal Officer Officer
Transaction date
Planned sale
Price
19.78
Quantity 5,196 -12.6%
Value US$102,783
VARKI PAUL Chief Legal Officer Officer
Transaction date
Planned sale
Price
18.91
Quantity 37,375 -47.5%
Value US$706,836
Sullivan Christopher Ryan Chief Financial Officer Officer
Transaction date
Planned sale
Price
22.57
Quantity 8,900 -95.5%
Value US$200,913
Sullivan Christopher Ryan Chief Financial Officer Officer
Transaction date
Planned sale
Price
21.37
Quantity 9,219 -49.7%
Value US$197,008
Sullivan Christopher Ryan Chief Financial Officer Officer
Transaction date
Planned sale
Price
20.76
Quantity 2,700 -12.7%
Value US$56,052
Sullivan Christopher Ryan Chief Financial Officer Officer
Transaction date
Planned sale
Price
19.28
Quantity 12,347 -36.8%
Value US$238,093
Sullivan Christopher Ryan Chief Financial Officer Officer
Transaction date
Planned sale
Price
18.55
Quantity 13,834 -29.2%
Value US$256,655
2.3
Doyle Mittie Chief Medical Officer Officer
Transaction date
Planned sale
Price
22.88
Quantity 10,058 -73.5%
Value US$230,127
2.3
Doyle Mittie Chief Medical Officer Officer
Transaction date
Planned sale
Price
22.41
Quantity 19,015 -58.2%
Value US$426,050
2.3
Doyle Mittie Chief Medical Officer Officer
Transaction date
Planned sale
Price
21.20
Quantity 44,944 -57.9%
Value US$952,669
2.3
Doyle Mittie Chief Medical Officer Officer
Transaction date
Planned sale
Price
19.65
Quantity 5,000 -6.1%
Value US$98,251
2.3
Doyle Mittie Chief Medical Officer Officer
Transaction date
Planned sale
Price
18.03
Quantity 27,538 -25.0%
Value US$496,405
Chan Mitchell Non-Executive Director
Transaction date
Planned sale
Price
22.88
Quantity 3,167 -50.0%
Value US$72,461
2.3
MITTIE DOYLE Officer Officer
Transaction date
Proposed sale
Price
16.26
Quantity 54,508
Value US$886,300
CHRISTOPHER SULLIVAN Officer Officer
Transaction date
Proposed sale
Price
16.26
Quantity 47,000
Value US$764,220
PAUL VARKI Officer Officer
Transaction date
Proposed sale
Price
16.26
Quantity 92,771
Value US$1,508,456
MITCHELL CHAN Director Non-Executive Director
Transaction date
Proposed sale
Price
16.26
Quantity 3,167
Value US$51,495
2.3
Doyle Mittie Chief Medical Officer Officer
Transaction date
Planned sale
Price
16.00
Quantity 1,679 -31.7%
Value US$26,864
Sullivan Christopher Ryan Chief Financial Officer Officer
Transaction date
Planned sale
Price
13.23
Quantity 8,457 -95.2%
Value US$111,853
Sullivan Christopher Ryan Chief Financial Officer Officer
Transaction date
Planned sale
Price
13.09
Quantity 8,458 -48.8%
Value US$110,736
CHRISTOPHER SULLIVAN Officer Officer
Transaction date
Proposed sale
Price
12.86
Quantity 16,915
Value US$217,527
2.3
Doyle Mittie Chief Medical Officer Officer
Transaction date
Planned sale
Price
18.01
Quantity 3,970 -52.3%
Value US$71,508
2.3
MITTIE DOYLE Officer Officer
Transaction date
Proposed sale
Price
17.76
Quantity 65,800
Value US$1,168,608
Sullivan Christopher Ryan Chief Financial Officer Officer
Transaction date
Planned sale
Price
17.57
Quantity 1,780 -9.3%
Value US$31,270
Sullivan Christopher Ryan Chief Financial Officer Officer
Transaction date
Planned sale
Price
17.02
Quantity 6,200 -24.5%
Value US$105,553
Sullivan Christopher Ryan Chief Financial Officer Officer
Transaction date
Planned sale
Price
16.83
Quantity 7,479 -22.8%
Value US$125,841
Sullivan Christopher Ryan Chief Financial Officer Officer
Transaction date
Planned sale
Price
15.86
Quantity 500 -1.5%
Value US$7,929
2.3
Doyle Mittie Chief Medical Officer Officer
Transaction date
Planned sale
Price
16.00
Quantity 679 -15.8%
Value US$10,864
CHRISTOPHER SULLIVAN Officer Officer
Transaction date
Proposed sale
Price
14.93
Quantity 15,959
Value US$238,268
2.3
Doyle Mittie Chief Medical Officer Officer
Transaction date
Sale
Price
16.15
Quantity 25,492 -87.6%
Value US$411,607
2.3
MITTIE DOYLE Officer Officer
Transaction date
Proposed sale
Price
15.80
Quantity 29,529
Value US$466,558
0.8
Goldman Jonathan Non-Executive Director
Transaction date
Sale
Price
14.35
Quantity 8,200 -100.0%
Value US$117,649
0.8
Goldman Jonathan Non-Executive Director
Transaction date
Sale
Price
14.30
Quantity 3,167 -100.0%
Value US$45,288
3.5
Almenoff June Sherie Non-Executive Director
Transaction date
Purchase
Price
13.00
Quantity 500 +100.0%
Value US$6,500
3.5
Almenoff June Sherie Non-Executive Director
Transaction date
Purchase
Price
12.50
Quantity 500 +inf%
Value US$6,250
2.7
ARMISTICE CAPITAL, LLC Large shareholder
Transaction date
Sale
Price
0.52
Quantity 937,404 -56.2%
Value US$486,888
2.7
ARMISTICE CAPITAL, LLC Large shareholder
Transaction date
Sale
Price
0.61
Quantity 2,746,138 -62.2%
Value US$1,682,010
NEIL GARRY ARTHUR CEO and Chairman of the Board Executive Director
Transaction date
Planned purchase
Price
3.42
Quantity 4,000 +43.4%
Value US$13,680
Sullivan Christopher Ryan Chief Financial Officer Officer
Transaction date
Planned purchase
Price
3.42
Quantity 511 +68.0%
Value US$1,748
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-09-18 2026-09-16 PlS Planned sale
Sullivan Christopher Ryan

Chief Financial Officer

Officer
96,897 +28.5%
471.31
US$1,162,085 		96,897 +28.5% 471.31 US$1,162,085
2026-09-11 2026-09-10 PlS Planned sale
Sullivan Christopher Ryan

Chief Financial Officer

Officer
71,656 +5.2%
188.36
US$3,455,060 		71,656 +5.2% 188.36 US$3,455,060
2026-09-01 2026-08-28 PlS Planned sale
2.3
Doyle Mittie

Chief Medical Officer

Officer
89,710 -13.9%
225.03
US$4,453,365 		89,710 -13.9% 225.03 US$4,453,365
2026-08-19 2026-08-18 S Sale
Sullivan Christopher Ryan

Chief Financial Officer

Officer
31,031 -43.7%
20.05
US$622,324 		31,031 -43.7% 20.05 US$622,324
2026-08-18 2026-08-18 PrS Proposed sale
CHRISTOPHER RYAN SULLIVAN

Officer

Officer
31,031
20.05
US$622,221 		31,031 20.05 US$622,221
2026-08-19 2026-08-17 S Sale
Sullivan Christopher Ryan

Chief Financial Officer

Officer
3,749 -8.6%
19.94
US$74,762 		3,749 -8.6% 19.94 US$74,762
2026-08-19 2026-08-17 PlS Planned sale
Sullivan Christopher Ryan

Chief Financial Officer

Officer
37,945 -46.5%
19.85
US$753,333 		37,945 -46.5% 19.85 US$753,333
2026-08-19 2026-08-17 PlS Planned sale
2.3
Doyle Mittie

Chief Medical Officer

Officer
1,000 -1.9%
20.00
US$20,000 		1,000 -1.9% 20.00 US$20,000
2026-08-17 2026-08-17 PrS Proposed sale
2.3
MITTIE DOYLE

Officer

Officer
5,037
19.59
US$98,675 		5,037 19.59 US$98,675
2026-08-17 2026-08-17 PrS Proposed sale
CHRISTOPHER RYAN SULLIVAN

Officer

Officer
70,709
19.59
US$1,385,189 		70,709 19.59 US$1,385,189
2026-08-17 2026-08-17 PrS Proposed sale
CHRISTOPHER RYAN SULLIVAN

Officer

Officer
3,749
19.94
US$74,762 		3,749 19.94 US$74,762
2026-08-12 2026-08-11 S Sale
Riley Jennifer

Chief Strategy Officer

Officer
2,655 -6.7%
19.59
US$52,012 		2,655 -6.7% 19.59 US$52,012
2026-08-11 2026-08-11 PrS Proposed sale
JENNIFER RILEY

Officer

Officer
2,655
19.59
US$52,012 		2,655 19.59 US$52,012
2026-08-12 2026-08-10 PlS Planned sale
2.3
Doyle Mittie

Chief Medical Officer

Officer
679 -1.3%
20.00
US$13,580 		679 -1.3% 20.00 US$13,580
2026-08-10 2026-08-10 PrS Proposed sale
2.3
MITTIE DOYLE

Officer

Officer
679
18.32
US$12,439 		679 18.32 US$12,439
2026-07-29 2026-07-27 PlS Planned sale
2.3
Doyle Mittie

Chief Medical Officer

Officer
1,000 -1.9%
20.00
US$20,000 		1,000 -1.9% 20.00 US$20,000
2026-07-02 2026-06-30 PlS Planned sale
2.3
Doyle Mittie

Chief Medical Officer

Officer
4,654 -8.2%
20.00
US$93,080 		4,654 -8.2% 20.00 US$93,080
2026-06-25 2026-06-23 PlS Planned sale
2.3
Doyle Mittie

Chief Medical Officer

Officer
1,450 -2.7%
18.00
US$26,100 		1,450 -2.7% 18.00 US$26,100
2026-06-02 2026-06-02 PrS Proposed sale
0.8
JONATHAN GOLDMAN

Director

Non-Executive Director
42,833
14.39
US$616,226 		42,833 14.39 US$616,226
2026-06-01 2026-05-28 PlS Planned sale
2.3
Doyle Mittie

Chief Medical Officer

Officer
679 -1.4%
16.00
US$10,864 		679 -1.4% 16.00 US$10,864
2026-05-19 2026-05-15 PlS Planned sale
2.3
Doyle Mittie

Chief Medical Officer

Officer
3,000 -45.3%
18.76
US$56,280 		3,000 -45.3% 18.76 US$56,280
2026-05-11 2026-05-07 PlS Planned sale
Sullivan Christopher Ryan

Chief Financial Officer

Officer
18,606 -97.8%
24.12
US$448,818 		18,606 -97.8% 24.12 US$448,818
2026-05-07 2026-05-07 PrS Proposed sale
CHRISTOPHER SULLIVAN

Officer

Officer
18,606
21.81
US$405,797 		18,606 21.81 US$405,797
2026-05-07 2026-05-06 PlS Planned sale
VARKI PAUL

Chief Legal Officer

Officer
400 -9.9%
23.71
US$9,484 		400 -9.9% 23.71 US$9,484
2026-05-07 2026-05-06 PlS Planned sale
VARKI PAUL

Chief Legal Officer

Officer
9,253 -69.6%
22.70
US$210,029 		9,253 -69.6% 22.70 US$210,029
2026-05-07 2026-05-06 PlS Planned sale
VARKI PAUL

Chief Legal Officer

Officer
22,839 -63.2%
21.22
US$484,541 		22,839 -63.2% 21.22 US$484,541
2026-05-07 2026-05-06 PlS Planned sale
VARKI PAUL

Chief Legal Officer

Officer
5,196 -12.6%
19.78
US$102,783 		5,196 -12.6% 19.78 US$102,783
2026-05-07 2026-05-06 PlS Planned sale
VARKI PAUL

Chief Legal Officer

Officer
37,375 -47.5%
18.91
US$706,836 		37,375 -47.5% 18.91 US$706,836
2026-05-07 2026-05-06 PlS Planned sale
Sullivan Christopher Ryan

Chief Financial Officer

Officer
8,900 -95.5%
22.57
US$200,913 		8,900 -95.5% 22.57 US$200,913
2026-05-07 2026-05-06 PlS Planned sale
Sullivan Christopher Ryan

Chief Financial Officer

Officer
9,219 -49.7%
21.37
US$197,008 		9,219 -49.7% 21.37 US$197,008
2026-05-07 2026-05-06 PlS Planned sale
Sullivan Christopher Ryan

Chief Financial Officer

Officer
2,700 -12.7%
20.76
US$56,052 		2,700 -12.7% 20.76 US$56,052
2026-05-07 2026-05-06 PlS Planned sale
Sullivan Christopher Ryan

Chief Financial Officer

Officer
12,347 -36.8%
19.28
US$238,093 		12,347 -36.8% 19.28 US$238,093
2026-05-07 2026-05-06 PlS Planned sale
Sullivan Christopher Ryan

Chief Financial Officer

Officer
13,834 -29.2%
18.55
US$256,655 		13,834 -29.2% 18.55 US$256,655
2026-05-07 2026-05-06 PlS Planned sale
2.3
Doyle Mittie

Chief Medical Officer

Officer
10,058 -73.5%
22.88
US$230,127 		10,058 -73.5% 22.88 US$230,127
2026-05-07 2026-05-06 PlS Planned sale
2.3
Doyle Mittie

Chief Medical Officer

Officer
19,015 -58.2%
22.41
US$426,050 		19,015 -58.2% 22.41 US$426,050
2026-05-07 2026-05-06 PlS Planned sale
2.3
Doyle Mittie

Chief Medical Officer

Officer
44,944 -57.9%
21.20
US$952,669 		44,944 -57.9% 21.20 US$952,669
2026-05-07 2026-05-06 PlS Planned sale
2.3
Doyle Mittie

Chief Medical Officer

Officer
5,000 -6.1%
19.65
US$98,251 		5,000 -6.1% 19.65 US$98,251
2026-05-07 2026-05-06 PlS Planned sale
2.3
Doyle Mittie

Chief Medical Officer

Officer
27,538 -25.0%
18.03
US$496,405 		27,538 -25.0% 18.03 US$496,405
2026-05-07 2026-05-06 PlS Planned sale
Chan Mitchell
Non-Executive Director
3,167 -50.0%
22.88
US$72,461 		3,167 -50.0% 22.88 US$72,461
2026-05-06 2026-05-06 PrS Proposed sale
2.3
MITTIE DOYLE

Officer

Officer
54,508
16.26
US$886,300 		54,508 16.26 US$886,300
2026-05-06 2026-05-06 PrS Proposed sale
CHRISTOPHER SULLIVAN

Officer

Officer
47,000
16.26
US$764,220 		47,000 16.26 US$764,220
2026-05-06 2026-05-06 PrS Proposed sale
PAUL VARKI

Officer

Officer
92,771
16.26
US$1,508,456 		92,771 16.26 US$1,508,456
2026-05-06 2026-05-06 PrS Proposed sale
MITCHELL CHAN

Director

Non-Executive Director
3,167
16.26
US$51,495 		3,167 16.26 US$51,495
2026-05-07 2026-05-05 PlS Planned sale
2.3
Doyle Mittie

Chief Medical Officer

Officer
1,679 -31.7%
16.00
US$26,864 		1,679 -31.7% 16.00 US$26,864
2026-05-01 2026-04-30 PlS Planned sale
Sullivan Christopher Ryan

Chief Financial Officer

Officer
8,457 -95.2%
13.23
US$111,853 		8,457 -95.2% 13.23 US$111,853
2026-05-01 2026-04-29 PlS Planned sale
Sullivan Christopher Ryan

Chief Financial Officer

Officer
8,458 -48.8%
13.09
US$110,736 		8,458 -48.8% 13.09 US$110,736
2026-04-29 2026-04-29 PrS Proposed sale
CHRISTOPHER SULLIVAN

Officer

Officer
16,915
12.86
US$217,527 		16,915 12.86 US$217,527
2026-04-08 2026-04-06 PlS Planned sale
2.3
Doyle Mittie

Chief Medical Officer

Officer
3,970 -52.3%
18.01
US$71,508 		3,970 -52.3% 18.01 US$71,508
2026-04-06 2026-04-06 PrS Proposed sale
2.3
MITTIE DOYLE

Officer

Officer
65,800
17.76
US$1,168,608 		65,800 17.76 US$1,168,608
2026-04-03 2026-04-02 PlS Planned sale
Sullivan Christopher Ryan

Chief Financial Officer

Officer
1,780 -9.3%
17.57
US$31,270 		1,780 -9.3% 17.57 US$31,270
2026-04-03 2026-04-02 PlS Planned sale
Sullivan Christopher Ryan

Chief Financial Officer

Officer
6,200 -24.5%
17.02
US$105,553 		6,200 -24.5% 17.02 US$105,553
2026-04-03 2026-04-01 PlS Planned sale
Sullivan Christopher Ryan

Chief Financial Officer

Officer
7,479 -22.8%
16.83
US$125,841 		7,479 -22.8% 16.83 US$125,841
2026-04-03 2026-04-01 PlS Planned sale
Sullivan Christopher Ryan

Chief Financial Officer

Officer
500 -1.5%
15.86
US$7,929 		500 -1.5% 15.86 US$7,929
2026-04-03 2026-04-01 PlS Planned sale
2.3
Doyle Mittie

Chief Medical Officer

Officer
679 -15.8%
16.00
US$10,864 		679 -15.8% 16.00 US$10,864
2026-04-01 2026-04-01 PrS Proposed sale
CHRISTOPHER SULLIVAN

Officer

Officer
15,959
14.93
US$238,268 		15,959 14.93 US$238,268
2026-03-18 2026-03-16 S Sale
2.3
Doyle Mittie

Chief Medical Officer

Officer
25,492 -87.6%
16.15
US$411,607 		25,492 -87.6% 16.15 US$411,607
2026-03-16 2026-03-16 PrS Proposed sale
2.3
MITTIE DOYLE

Officer

Officer
29,529
15.80
US$466,558 		29,529 15.80 US$466,558
2025-11-17 2025-11-14 S Sale
0.8
Goldman Jonathan
Non-Executive Director
8,200 -100.0%
14.35
US$117,649 		8,200 -100.0% 14.35 US$117,649
2025-11-17 2025-11-14 S Sale
0.8
Goldman Jonathan
Non-Executive Director
3,167 -100.0%
14.30
US$45,288 		3,167 -100.0% 14.30 US$45,288
2024-11-14 2024-11-13 B Purchase
3.5
Almenoff June Sherie
Non-Executive Director
500 +100.0%
13.00
US$6,500 		500 +100.0% 13.00 US$6,500
2024-11-14 2024-11-12 B Purchase
3.5
Almenoff June Sherie
Non-Executive Director
500 +inf%
12.50
US$6,250 		500 +inf% 12.50 US$6,250
2023-06-28 2023-06-27 S Sale
2.7
ARMISTICE CAPITAL, LLC
Large shareholder
937,404 -56.2%
0.52
US$486,888 		937,404 -56.2% 0.52 US$486,888
2023-06-28 2023-06-26 S Sale
2.7
ARMISTICE CAPITAL, LLC
Large shareholder
2,746,138 -62.2%
0.61
US$1,682,010 		2,746,138 -62.2% 0.61 US$1,682,010
2023-06-20 2023-06-20 B Purchase
1.6
Caissa Capital Management ltd.
Large shareholder
2,000 +0.1%
4.14
US$8,289 		2,000 +0.1% 4.14 US$8,289
2023-06-20 2023-06-16 B Purchase
1.6
Caissa Capital Management ltd.
Large shareholder
3,000 +0.2%
3.90
US$11,714 		3,000 +0.2% 3.90 US$11,714
2023-06-20 2023-06-15 B Purchase
1.6
Caissa Capital Management ltd.
Large shareholder
3,160 +0.2%
3.68
US$11,640 		3,160 +0.2% 3.68 US$11,640
2023-06-14 2023-06-14 B Purchase
1.6
Caissa Capital Management ltd.
Large shareholder
6,000 +0.4%
3.48
US$20,874 		6,000 +0.4% 3.48 US$20,874
2023-06-14 2023-06-13 B Purchase
1.6
Caissa Capital Management ltd.
Large shareholder
8,750 +0.6%
3.82
US$33,439 		8,750 +0.6% 3.82 US$33,439
2023-06-14 2023-06-12 B Purchase
1.6
Caissa Capital Management ltd.
Large shareholder
2,149 +0.2%
4.34
US$9,316 		2,149 +0.2% 4.34 US$9,316
2023-06-13 2023-06-09 PP Planned purchase
NEIL GARRY ARTHUR

CEO and Chairman of the Board

Executive Director
4,000 +43.4%
3.42
US$13,680 		4,000 +43.4% 3.42 US$13,680
2023-06-13 2023-06-09 PP Planned purchase
Sullivan Christopher Ryan

Chief Financial Officer

Officer
511 +68.0%
3.42
US$1,748 		511 +68.0% 3.42 US$1,748
2023-06-09 2023-06-09 B Purchase
1.6
Caissa Capital Management ltd.
Large shareholder
5,044 +0.4%
4.14
US$20,896 		5,044 +0.4% 4.14 US$20,896
2023-06-09 2023-06-08 B Purchase
1.6
Caissa Capital Management ltd.
Large shareholder
6,398 +0.5%
3.93
US$25,126 		6,398 +0.5% 3.93 US$25,126
2023-06-09 2023-06-07 B Purchase
1.6
Caissa Capital Management ltd.
Large shareholder
2,984 +0.2%
3.49
US$10,418 		2,984 +0.2% 3.49 US$10,418
2023-06-02 2023-05-31 B Purchase
1.6
Caissa Capital Management ltd.
Large shareholder
844 +0.1%
2.87
US$2,422 		844 +0.1% 2.87 US$2,422
Explore more

More insider trading research around Avalo Therapeutics, Inc.

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America